Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead asset MM120 for the treatment of generalized anxiety ...
Fintel reports that on January 21, 2026, Chardan Capital initiated coverage of Alumis (NasdaqGS:ALMS) with a Buy recommendation. Analyst Price Forecast Suggests 39.23% Upside As of January 14, 2026, ...
NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series ...
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the ...
Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 clinical trial of its lead autologous CD22 CAR-T ...
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today ...
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the ...
LOS ANGELES--(BUSINESS WIRE)--Surf Air Mobility Inc. (NYSE: SRFM) (“Surf Air Mobility”) Co-founder Sudhin Shahani and CFO Oliver Reeves participated in Chardan’s Transport Platform Tech Series virtual ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the 12 Best Genomics Stocks to Invest In. TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results